Analysts: Johnson & Johnson Drug Revenue Could Double and 3 More Research Notes to Read
Johnson & Johnson (NYSE:JNJ): Wells Fargo is expecting that the revenue generated by four of the company’s new drugs could double from 2012 to 2015, after attending the company’s bi-annual pharmaceutical business review. With the belief that the company’s pharmaceutical units is one of the best in the industry, it keeps an Outperform rating on the shares.
Nordson (NASDAQ:NDSN): Weak Q3 guidance and valuation pressed BMO Capital to downgrade Nordson from Outperform to Market Perform, and reduce its price target from $74 to $72. It also points out that Nordson was downgraded by Oppenheimer earlier.
The Gap, Inc. (NYSE:GPS): Jefferies keeps The Gap as a top pick after its Q1 results, and says that Gap continues to benefit from structural improvements and elevated talent. The firm keeps a Buy rating and $56 price target.
DDR Corp. (NYSE:DDR): Jefferies has brought DDR from Hold to Buy, based on expectations that the company will reach its five-year operating plan early ahead of expectations.The price target has also been raised to $22, from $20.